First-line Disitamab Vedotin/Toripalimab Ups Survival in HER2+ mUC
Disitamab vedotin with toripalimab improved PFS and OS over chemo in HER2-expressing metastatic urothelial carcinoma, per phase 3 trial interim analysis.
Related Articles
BCI, Patient Preference Guide Nurses in 5-Year Endocrine Counseling
The BCI and patient goals help oncology nurses counsel patients on endocrine therapy use after 5 years, per Michelle Kirschner RN, MSN, ACNP, APRN-BC.
Anemia Protocol Does Not Reduce Ruxolitinib Efficacy in Myelofibrosis
Adding danazol or erythropoiesis-stimulating agents for anemia management to a ruxolitinib regimen for myelofibrosis does not decrease treatment efficacy.
Rx Road Map: Durvalumab for Non-Small Cell Lung Cancer
Read Stacey Hield, BSN, RN, OCN’s recommendations for best use of durvalumab in non-small cell lung cancer.
Genomic Changes May Drive Sotorasib KRAS G12C+ Combo Resistance in CRC
Biomarker data from CodeBreaK 300 suggest DNA and RTK pathway alterations may underlie resistance to sotorasib plus panitumumab in CRC.
FDA Approves Tafasitamab Combo for R/R Follicular Lymphoma
The FDA has approved tafasitamab in combination with lenalidomide and rituximab for adults with relapsed/refractory follicular lymphoma.
CDK4/6 Inhibition Customizes Frontline HR+, HER2- mBC Treatment
According to Kimberly Podsada, BSN, RN, MSN, NP-C, CNS, the availability of 3 CDK4/6 inhibitors in first-line mBC therapy gives patients more choices.
No One Should Face Cancer Alone: The Power of Community in Cancer Care
Ask patients, “Who’s in your corner?”
Nurses’ Role in Grief Support for Pediatric Brain Cancer Survival
Oncology nurses can help patients and families understand the expectations of pediatric brain cancer survival, says Kasey Rangan, MSN, CPNP-PC, CPHON.
Oncology Nurses Aid BC Survivorship and Lymphedema Prevention
Because oncology nurses are at the forefront of patient care, they are uniquely positioned to facilitate cancer survivorship and lymphedema prevention.
Opinion: Topical BRAF Inhibitor Could Reduce Rash in Anti-EGFR Therapy
Oncology nurses can play a key role in educating patients and supporting clinical trial participation for this new treatment option.